Natural amylin breaks down within minutes
Regulatory Status and Quality Considerations BPC-157 currently lacks approval from the United States Food and Drug Administration (FDA) or other major regulatory authorities for any therapeutic indication
The intramuscular route is often chosen for the first treatment because it works well
Investors believe its a $1-billion-to-$3-billion-a-year market, but hard figures are elusive, because most peptides are sold on the quasi-legal gray market
Because angiogenesis is a defining hallmark of tumor growth and metastatic progression, any therapeutic agent that enhances neovascularization could, in theory, facilitate tumor expansion and promote metastatic dissemination
Angiogenesis helps heal wounds by improving blood supply, but in cancer, new blood vessels feed tumors and facilitate their spread